Loading organizations...
Home Biosciences operates as a pioneering biotech venture builder, focused on identifying, creating, and advancing transformative medicines. The company primarily leverages a unique, large human multi-modal single-cell dataset to discover and develop novel anti-fibrotic drug candidates for patients suffering from fibrotic diseases. This asset-centric operating model aims to unlock scientific breakthroughs and expedite the development of new therapeutic options.
The company was founded in 2019 by Magali Richard, establishing itself as Europe’s first venture builder fully dedicated to biotechnology. Richard's insight was to create an innovative framework that provides both financial and operational support, fostering the growth of groundbreaking therapies from inception. This model addresses significant gaps in early-stage biotech development, aiming to streamline the often complex path from discovery to clinical application.
Home Biosciences is dedicated to generating life-changing medicines for patients who currently have poor or no therapeutic options. The company's long-term vision is to build a robust portfolio of transformative therapies by identifying and accelerating promising research. Its ultimate goal is to bring these critical medicines to market, thereby significantly improving patient outcomes across various debilitating conditions.
Home Biosciences has raised $15.0M across 1 funding round.
Home Biosciences has raised $15.0M in total across 1 funding round.
# Home Biosciences: A Biotech Venture Builder
Home Biosciences is not primarily a technology company, but rather a biotech venture builder—a novel operating model designed to create and scale transformative medicines more efficiently than traditional biotech startups.[1] The distinction is important: while it leverages technology and data science, its core mission centers on identifying, building, and advancing therapeutic companies addressing unmet medical needs.
Home Biosciences operated as Continental Europe's first venture builder fully dedicated to biotechnology, functioning as an asset-centric platform that combined funding, operational expertise, and drug development infrastructure under one roof.[1] Rather than developing a single product, it co-founded and incubated multiple biotech ventures, each pursuing distinct therapeutic areas.
The company's mission was to maximize capital efficiency and accelerate time-to-value by eliminating the need for early-stage ventures to build expensive corporate infrastructure independently.[2] Its investment philosophy centered on identifying groundbreaking scientific projects with academic partners, assembling dedicated execution teams, and providing rigorous operational oversight to de-risk development pathways.[1]
However, Home Biosciences ended day-to-day operations in January 2025 and transitioned to a non-operating mode focused on building value for its co-founded companies going forward.[1]
Home Biosciences was co-founded in late 2019 by Magali Richard and David Schilansky, two biotech industry veterans with complementary expertise spanning drug development, operational execution, and funding.[2] The founding was backed by prominent biotech investors Redmile Group and Sofinnova Partners, who recognized the need for a novel model to jumpstart innovation in the European biotech ecosystem.[1]
Over five years, the venture builder successfully created three companies from scratch:[1]
Home Biosciences' operating model distinguished it through several key features:
Home Biosciences addressed a critical gap in the European biotech landscape: the capital inefficiency and infrastructure burden facing early-stage therapeutic companies.[2] While the U.S. venture-backed biotech model had matured, Europe lacked comparable mechanisms to rapidly translate academic breakthroughs into clinical-stage companies.
The venture builder model itself represents a trend toward operational integration in biotech—recognizing that scientific excellence alone is insufficient without disciplined execution, funding stability, and strategic guidance. By concentrating these elements, Home Biosciences demonstrated that European biotech could compete with U.S. models while maintaining deep academic roots.
The company's transition to non-operating status in 2025 reflects both the success of its model (ventures were sufficiently mature to operate independently) and the broader maturation of the European biotech ecosystem, which now supports standalone company formation more readily than in 2019.
Home Biosciences' legacy lies not in a single product or service, but in proving a replicable template for European biotech creation. Its three co-founded companies—particularly One Biosciences, now operating as an independent techbio firm with AI-driven capabilities—represent the tangible outcomes of this model.
The venture builder's shift to non-operating mode suggests confidence in its portfolio companies' ability to execute independently while maintaining Home Biosciences' strategic involvement in value creation. The success or failure of these ventures will ultimately validate whether the venture builder model can compete with traditional biotech funding and development approaches in delivering transformative medicines to patients.
Home Biosciences has raised $15.0M in total across 1 funding round.
Home Biosciences's investors include Soffinova Partners, Ming Fang, Sofinnova Investments.
Home Biosciences has raised $15.0M across 1 funding round. Most recently, it raised $15.0M Seed in November 2021.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Nov 1, 2021 | $15.0M Seed | Soffinova Partners, Ming Fang | Sofinnova Investments |